A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

Study ID: 4267
NCT Number: NCT06339008
Principal Investigator: Christine Franzese, MD
Department: Otolaryngology
Eligibility: Both men and women 18 years old to 110 years old. Does not accept healthy volunteers.